HIGH GH basal levels in patients with type 1 diabetes
|
|
- Jeffry Chambers
- 5 years ago
- Views:
Transcription
1 X/98/$03.00/0 Vol. 83, No. 10 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1998 by The Endocrine Society Growth Hormone (GH) Response to GH-Releasing Peptide-6 in Type 1 Diabetic Patients with Exaggerated GH-Releasing Hormone-Stimulated GH Secretion* PABLO F. CATALINA, FEDERICO MALLO, M. AMELIA ANDRADE, RICARDO V. GARCíA-MAYOR, AND CARLOS DIÉGUEZ Departments of Endocrinology, Montecelo Hospital, Pontevedra (P.F.C.), and Xeral-Cíes Hospital, Vigo (M.A.A., R.V.G.-M.). Department of Functional Biology and Health Sciences, University of Vigo (F.M.); and Department of Physiology, University of Santiago de Compostela (C.D.); Spain. ABSTRACT In type 1 diabetes mellitus (DM 1), high GH basal levels and exaggerated GH responses to several stimuli, including GHRH, have been described. GH-releasing peptide-6 (GHRP-6) is a synthetic hexapeptide that specifically stimulates GH release, both in vitro and in vivo. The aim of this study was to evaluate the effects of GHRP-6 alone or in combination with GHRH on GH secretion in DM 1. Six type 1 diabetic males and six age-, sex-, and body mass index-matched control volunteers were studied. Each subject received GHRH (100 g iv), GHRP-6 (90 g iv), and GHRH plus GHRP-6 on three separate days. GH peak values were higher in DM 1 patients than in control volunteers, after GHRH ( vs g/l; P 0.016), GHRP-6 ( vs g/l; P 0.05), and GHRH plus HIGH GH basal levels in patients with type 1 diabetes mellitus (DM 1) were described 3 decades ago (1). For many years, this has been explained as an epiphenomenon of poor metabolic control. In normal subjects, hyperglycemia inhibits pituitary GH response to provocative stimuli. Nevertheless, DM 1 patients, despite elevated blood glucose levels, show exaggerated GH responses to several physiological and pharmacological provocative tests (2 7), and they have mean 24-h GH levels higher than those of normal subjects (8, 9). However, recently it has been shown that, in DM 1, the administration of GH-releasing peptide-6 (GHRP-6) and GHRH (either alone or in combination) induces GH release similar to that in healthy subjects (10). Although GHRH and SRIF have a predominant role in the regulation of the pulsatile pattern of GH secretion, other hypothalamic factors can modulate GH release from the anterior pituitary. GHRP-6 is a synthetic hexapeptide that specifically stimulates GH release, both in vitro and in vivo. This peptide acts in man in a dose-related manner, and it activates pituitary and hypothalamic receptors. It does not operate through GHRH receptors or modulate endogenous GHRH release (11). Received February 5, Revision received June 18, Accepted June 30, Address all correspondence and requests for reprints to: Federico Mallo, Department of Functional Biology and Health Sciences, Faculty of Sciences, Campus of Vigo, University of Vigo, Vigo, Spain E * This work was supported by funding from the Fondo de Investigaciones Sanitarias (FIS 96/1739). GHRP-6 ( vs g/l; P 0.01). An additive GH response to combined administration of these two peptides was observed in diabetic patients. Serum insulin-like growth factor (IGF)-1 levels were diminished in DM 1, with respect to normal subjects ( vs g/l; P 0.01), whereas IGF-binding protein-3 levels were not significantly different between DM-1 and controls. In summary, GHRP-6 is a potent stimulus for GH secretion in DM 1. The combined administration of GHRP-6 plus GHRH constitutes the most powerful stimulus for GH secretion in DM 1. These patients exhibit a greater GH secretory capacity than normal subjects, probably caused by a diminished tone in the IGF-1 sustained negative feedback control exerted upon somatotroph responsiveness. (J Clin Endocrinol Metab 83: , 1998) The administration of GHRH plus GHRP-6 at maximal doses exerts a synergistic effect on GH secretion in normal subjects. This combined stimulus, which represents the most potent GH releaser to date, is being used to elucidate the physiology of GH neuroregulation, as well as its alterations, in several disease states. Its in vivo synergism suggests that GHRP-6 acts at both pituitary and hypothalamic levels, although the GHRP-6 mechanism of action is unknown. It has been postulated that it may exerts most of its actions at hypothalamic level, perhaps releasing and/or inducing the secretion of an unknown hypothalamic peptide or factor (11 13). The aim of this study was to evaluate the effects of GHRP-6, alone or in combination with GHRH, on GH secretion in a group of DM 1 patients. Subjects Subjects and Methods Six male patients with DM 1, with a mean age of 28.3 yr (range, yr) and a body mass index (BMI) varying from kg/m 2 (mean, 24.3 kg/m 2 ) were studied. The clinical characteristics of the patients are reported in Table 1. All of these patients had normal thyroid and renal function, and none was taking any medication other than insulin. DM 1 subjects followed an appropriate diet and were all taking a mixture of short- and intermediate-acting insulin by sc injections, twice daily. Background retinopathy, determined with retinal fluorescein angiography, was present in two patients. Incipient diabetic nephropathy was detected in the same two patients. None of the patients had other associated diseases. The control group consisted of six normal males with no familiar 3663
2 3664 CATALINA ET AL. JCE&M 1998 Vol 83 No 10 TABLE 1. Clinical characteristics of the subsets studied history of diabetes mellitus. Their mean age was 28.6 yr (range, yr), and their mean BMI was 23.4 kg/m 2 (range, kg/m 2 ). All subjects in this group had normal thyroid function and were free of any medication at the time of the study. Study protocol The experimental protocol was approved by the ethics committee of Xeral-Cíes Hospital. All subjects were studied after giving informed consent. All tests were performed after habituation to the hospital setting. The experiments started at 0900 h, after an overnight fast, with the subjects recumbent. DM 1 patients did not receive morning insulin injection until the end of each test. Sixty minutes before starting the test, an indwelling catheter was placed in a forearm vein and kept patent by slow 0.9% saline infusion. Each subject underwent three tests, randomly, with an interval of at least 1 week, so each subject served as his own control. After basal samples for measuring GH, insulin-like growth factor (IGF)-1, and IGF-binding protein-3 (IGFBP-3) levels, patients and controls received GHRH, GHRP-6, or GHRH plus GHRP-6 at 0 min, and blood sampling continued until 150 min. GHRH [GRF-(1 29))NH 2, Geref Serono, Madrid, Spain] was administered at a dose of 100 g iv. On a subsequent day, GHRP-6 (Peninsula Laboratories, Inc., Heyerside, UK), formulated and tested at the Complejo Hospitalario de Santiago pharmacy, was administered at a dose of 90 g iv. On a separate day, GHRH plus GHRP-6, at the above doses, was administered iv. Assays Serum GH levels were measured in duplicate by a highly sensitive two-site monoclonal antibody immunoradiometric assay (hgh Allegro, Nichols Institute Diagnostics, San Juan Capistrano, CA). The sensitivity of the method is 0.02 g/l. The mean intraassay coefficients of variation (CVs) were 2.5% (2.6 g/l), 3.8% (6.9 g/l), and 2.6% (13 g/l). The interassay CVs were 2.9% (2.6 g/l), 3.4% (6.9 g/l), and 2.5% (13 g/l). All samples from each subject were analyzed in the same assay. IGF-1 was determined by a commercially available RIA (Nichols Institute Diagnostics). The intra- and interassay CVs were 2.4% (110 g/l) and 3% (338 g/l), 3.8% (562 g/l) and 5.2% (121 g/l), and 6.5% (371 g/l) and 6.8% (641 g/l), respectively. Another commercially available RIA (Mediagnostic GMbH; Tubingen, Germany) was used for the measurement of IGFBP-3 levels. The intraassay CVs were 2.8% (2.2 mg/l) and 3% (4.3 mg/l) and the interassay CVs were 4.8% (2.6 mg/l) and 5.9% (4.5 mg/l). HbA 1c levels were measured by high-performance liquid chromatography (Menarini, Italy; normal range 5.8%). Statistical analysis n Age (yr) BMI (kg/m 2 ) Data are presented and analyzed as absolute values, and results are reported as the mean sem. We calculated the peak GH value (maximum GH level measured within 150 min after the stimulus); the mean GH values; the time in which the peak GH value was obtained (T peak), and the AUC (area under the response curve). Friedman s ANOVA was performed to compare GH levels in each group studied. The Mann- Whitney test was used for comparisons between different groups. The GH response to each test was also analyzed by the AUC, which was calculated by a trapezoidal method. Undetectable GH levels ( 0.02 g/l) were considered to be equal to 0.05 g/l for statistical purposes. The statistical level of significance was established at P Results The GH responses to the different stimuli are depicted in Fig. 1. The secretory GH parameters obtained in both groups Duration of disease (months) Insulin dose (U/kg day) Hb A 1c (%) Control (26 32) ( ) ( ) DM (24 35) ( ) (75 312) ( ) ( ) Mean SEM (range). Hb A 1c, Hemoglobin type A 1c. FIG. 1. Mean SEM. GH responses to GHRH (A), GHRP-6 (B), and GHRH plus GHRP-6 (C), in DM-1 ( ) and control subjects (f). *, P 0.05; **, P are shown in Table 2. There were no significant differences in basal GH values between the experiments in both groups. When challenged with a maximal dose of GHRH, normal subjects showed the expected prompt GH peak of g/l. On the other hand, the injection of a maximal dose of GHRP-6 was also a potent GH releaser, with a peak of g/l. The combined administration of both GH secretagogues at the same doses induced a large peak of g/l. In control subjects, the mean GH level after GHRH administration did not differ significantly from that after GHRP-6. The AUC after GHRH administration was g/l 150 min and g/l 150 min, after GHRP-6 injection [P NS (not significant)]. The administration to these normal volunteers of GHRH plus GHRP-6 at
3 GH RESPONSE TO GHRP-6 IN DIABETICS 3665 TABLE 2. Secretory GH parameters the same doses induced a synergistic GH release (AUC, g/l 150 min; P 0.04). In DM 1 patients, the GHRH-induced GH peak was g/l, whereas the GHRP-6-induced GH peak was g/l. A peak of g/l was obtained after the combined administration of GHRH plus GHRP-6 (P 0.005). When the AUCs were analyzed ( g/l 150 min), GHRHinduced GH release was , whereas GHRP- 6-induced secretion was The GH discharge after GHRH plus GHRP-6 treatment was There were clear differences in the AUCs when GHRH and GHRP-6 were administered alone, compared with their combined injection (P 0.01). The combined administration of both GH releasers showed an additive effect, rather than a synergistic action. When DM 1 patients were compared with the control group, significantly greater GH responses to GHRH, to GHRP-6, and to GHRH plus GHRP-6 were observed in the DM 1 group (Fig. 1). No side effects were reported in any of the subjects tested. Basal serum IGF-1 levels were significantly lower in the DM 1 patients than in the control group ( vs g/l, respectively; P 0.01). We did not find statistical differences in IGFBP-3 values between DM 1 patients and healthy controls ( vs mg/l, respectively; P 0.20). Discussion Basal GH DM 1 is associated with marked perturbations of the GH/ IGF-1 axis. It has been described as an increased spontaneous GH secretion, but also patients with DM 1 may show exaggerated GH responses to different provocative stimuli such as exercise, arginine, clonidine, dopamine, levodopa, or GHRH (2 7). Twenty-four-hour integrated serum GH concentrations are also elevated in DM 1, because of increases in both the frequency and peak amplitude of GH secretory pulses (8, 9). IGF-1 levels are either normal or reduced, and there is evidence of a reversible defect in IGF-1 generation in these patients (9, 14, 15). This disrupted GH secretion may have relevant physiopathological implications. Several experimental studies suggest the possible relationship between abnormal GH regulation and the development of diabetic microvascular disease (16 19). Historical studies, both in humans and in animal models, reported the amelioration of Peak GH Mean GH T peak (min) AUC ( g/l 150 min) GHRH Control DM Mann-Whitney NS NS GHRP-6 Control DM Mann-Whitney NS NS NS GHRH GHRP-6 Control DM Mann-Whitney NS NS Mean SEM. Comparison by nonparameter Mann Whitney s test. For description, see Subjects and Methods. biochemical abnormalities after hypophysectomy or the development of hypopituitarism (20, 21). Moreover, this altered GH secretion may play a potential role in mediating the metabolic derangement of DM 1 (22). Therefore, long-term correction of GH/IGF-1-axis abnormalities in DM 1 may be an important consideration in the development of therapeutic modalities aimed at not only improving metabolic control but also at preventing the pathological sequelae associated with DM 1. Elevated circulating GH levels in subjects with DM 1 have been reported by numerous studies during the past 3 decades (1, 23, 24). The chronic exposure to a hyperglycemic milieu may be important in the pathogenesis of these defects, because circulating glucose level is a potent regulator of GH secretion. Therefore, defects in both glucose and insulin homeostasis may contribute to abnormal regulation of GH in DM 1. At present, the underlying mechanisms responsible for somatotropinergic axis alterations in patients with DM 1 are still not well understood. To gain further insight into mechanisms of altered GH secretion in DM 1, we assessed pituitary GH reserve in these patients, after challenge with the most potent GH-secretagogues available in the clinical setting (namely, GHRH and GHRP-6, administered alone or in combination). Although not a universal finding, some previous studies have found that DM 1 patients exhibited a GH response, after GHRH administration, greater than that of normal subjects (7, 25). These augmented responses to GHRH could not be demonstrated by various other authors (14, 26). Although unclear, at present, these discrepancies could be caused by the known variability in GH responses to GHRH in normal subjects and/or the differences in the patients characteristics, i.e. sex, BMI, adequate metabolic control, etc. Our results confirm that DM 1 patients have an exaggerated GH response to GHRH. In the last few years, GHRP-6 has been employed as a useful tool for exploring GH secretory mechanisms in different states of deranged GH secretion, such as obesity, acromegaly, Cushing syndrome, alterations of growth, or polycystic ovary syndrome, among others (27 31). GHRP-6 activates specific somatotroph and hypothalamic receptors distinct from GHRH receptors (32). It does operate through GHRH-independent mechanisms, and its intracellular signaling system seems to be different from those for GHRH. In
4 3666 CATALINA ET AL. JCE&M 1998 Vol 83 No 10 addition, the combined administration of GHRH plus GHRP-6 represents the most powerful GH secretagogue in most pathophysiological circumstances (13). Confirming previous reports, in our study, a greater GHRP-6-induced GH response was observed in normal subjects (33). When GHRP-6 and GHRH were given together, we observed a synergistic effect, as shown previously (12, 29). This could be explained by the existence of specific receptors for each peptide, at pituitary and hypothalamic levels (32). We also observed that GHRP-6 constitutes a secretagogue of GH secretion, in DM 1 patients, at least as potent as GHRH. Moreover, GH responses to GHRP-6 were higher in DM 1 patients than in normal controls. A GH discharge of such magnitude has never been obtained with other secretagogues in DM 1, despite the multiple stimuli studied (2 7), confirming that GHRP-6 represents one of the most powerful GH secretagogues described to date in DM 1 subjects. It has been reported that acute oral glucose administration blunts the GH response to hexarelin, a GHRP-6 analogue, in normal subjects (34), which might indicate that, indeed, a normal GH response to GHRP-6 in DM 1 patients could also be considered exaggerated. Augmented GHRP-6-induced GH response in DM 1 subjects suggests that GH hypersecretion, in this disease state, is not mediated only by endogenous hypothalamic GHRH or somatostatinergic secretion. Having been proven that GHRP-6 specific binding sites on hypothalamus and pituitary exist (32), it is possible that an endogenous GHRP-like ligand mediates, at least partially, this disarranged GH secretion shown in these patients. Although basal GH secretion is elevated in DM 1 patients, and the ability to respond to both GHRP-6 and GHRH is enhanced, the higher GHRH plus GHRP-6 induced-gh response observed suggests that there is still a considerable reserve of GH in the somatotroph cells ready to be secreted on demand. This fact points out that, in the somatotroph cells of these patients, the GH synthesis might be also augmented. Further in vitro studies will be necessary to confirm this hypothesis. However, we were not able to find the synergistic effect of those peptides when administered together in DM 1, as shown for control volunteers. It seems that this combined administration reaches the maximal capacity of somatotroph responsiveness, both in controls and DM 1 patients (being higher in DM 1). Thus, the additive effect observed in GHRH GHRP-6-induced GH responses in DM1 is probably caused by the high response elicited by each peptide alone. On the other hand, in a previous report, Vilas-Boas et al. (10) were not able to demonstrate any differences in GH responses to the administration of GHRP-6 and GHRH, either alone or in combination, in DM 1 patients, compared with normal subjects. Moreover, they did not find differences in the responses of GH elicited by GHRH and GHRP-6 in DM1, even in normal volunteers, as would be expected considering previous reports (11, 12). However, they found a synergistic effect of GHRH and GHRP-6 when they where administered together, both in DM 1 and controls. These discrepancies could be explained, because Vilas- Boas et al. studied a nonsex-matched group (including male and female) and did not find any statistical differences in IGF-1 total serum levels between DM 1 and normal subjects. Meanwhile, we studied sex-, age- and BMI-matched groups, and the IGF-1 total levels found in DM 1 patients were markedly lower than those found in normal volunteers. Most of our data might be explained by a diminished negative feedback exerted by the circulating IGF-1 levels upon the GH secretion by the pituitary. As shown in Results, we found a reduction in total serum IGF-1 values in DM 1 patients, with respect to controls. This indicates a partial lack of inhibiting control upon somatotroph GH secretion. These data became more relevant when IGF-BP3 levels were shown to be not significantly different in DM 1 from those in control volunteers. Considering that IGF-BP3 binds nearly 90% of circulating IGF-1, the fact that DM 1 showed IGF-BP3 levels similar to controls, and reduced IGF-1 total levels, implies that circulating IGF-1 free-fraction must be markedly reduced in DM 1, in comparison with normal subjects. This could emphasize the fact that a reduction in serum IGF-1 total levels would have marked influence in the physiological control of the somatotrophic axis. In summary, we have shown that DM 1 patients have an elevated GH response to GHRP-6 and GHRH. The combined administration of these two peptides has an additive effect and constitutes the most powerful stimulus for GH secretion in DM 1 subjects. Our data suggest that patients with DM 1 exhibit a greater GH secretory capacity than control subjects, possible caused by a diminished negative feedback control exerted by the IGF-1 upon somatotroph responsiveness. Acknowledgments We are grateful to Aurora Carballo, María José Casado, Pilar Cerqueira, and Luis Teniente for their assistance in conducting the experiments and in the analysis of hormonal samples. References 1. Hansen AP, Johansen K Diurnal patterns of blood glucose, serum free fatty acids, insulin, glucagon and growth hormone in normals and juvenile diabetics. Diabetologia. 6: Hansen AP Abnormal serum growth hormone response to exercise in juvenile diabetics. J Clin Invest. 49: Speroni G, Ceda GP, Capretti L, Valenti G Clonidine and GH secretion in insulin dependent diabetes (IDD). Horm Metab Res. 15: Burday SZ, Fine PH, Schalch DS Growth hormone secretion in response to arginine infusion in normal and diabetic subjects: relationship to blood glucose levels. J Lab Clin Med. 71: Ajlouni K, Martinson DR, Hagen TC Effect of glucose on the growth hormone response to L-dopa in normal and diabetic subjects. Diabetes. 24: Lorenzi M, Karam JH, McIlroy MB, Forsham PH Increased growth hormone response to dopamine infusion in insulin-dependent diabetic subjects. J Clin Invest. 65: Krassowski J, Felber JP, Rogala H, Jeske W, Zgliczynski S Exaggerated growth hormone response to growth hormone-releasing hormone in type I diabetes mellitus. Acta Endocrinol (Copenh). 117: Edge JA, Dunger DB, Matthews DR, Gilbert JP, Smith CP Increased overnight growth hormone concentrations in diabetic compared with normal adolescents. J Clin Endocrinol Metab. 71: Asplin CM, Faria ACS, Carlsen EC, et al Alterations in the pulsatile mode of growth hormone release in men and women with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 69: Villas-Boas RF, Ramos-Dias JC, Chipoch C, Lengyel AMJ Growth hormone (GH) response to GH-releasing peptide-6 in patients with insulindependent diabetes mellitus. Metabolism. 46: Micic D, Mallo F, Peinó R, et al Regulation of growth hormone secretion by the growth hormone releasing hexapeptide (GHRP-6). J Pediatr Endocrinol. 6: Peñalva A, Carballo A, Pombo M, Casanueva FF, Diéguez C Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6 induced GH secretion in man. J Clin Endocrinol Metab. 76:
5 GH RESPONSE TO GHRP-6 IN DIABETICS Ghigo E, Arvat E, Muccioli G, Camanni F Growth hormone-releasing peptides. Eur J Endocrinol. 136: Press M, Tamborlane WV, Thorner MO, et al Pituitary response to growth hormone-releasing factor in diabetes. Failure of glucose-mediated suppression. Diabetes. 33: Horner JM, Kemp SF, Hintz RL Growth hormone and somatomedin in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 53: Alzaid AA, Melton LJ, Dinneen SF, Rizza RA The role of growth hormone in the development of diabetic retinopathy. Diabetes Care. 17: Sharp PS The role of growth factors in the development of diabetic retinopathy. Metabolism. [Suppl 4]44: Feld S, Hirschberg R Growth hormone, the insulin-like growth factor system and the kidney. Endocr Rev. 17: Muchaneta-Kubara EC, Sayed-Ahmed N, Besbas N, Zhang G, Cope GH, El Nahas AM Experimental diabetic renal growth: role of growth hormone and insulin-like growth factor I. Nephrol Dial Transplant. 9: Houssay BA, Magenta MA Sensibilidad en los perros hipofisoprivos a la insulina. Rev Asoc Med Arg (Soc Biol). 37: Lyall A, Innes JA Diabetes mellitus and the pituitary gland. A case of diabetes with intercurrent pituitary lesion and concomitant improvement of diabetes. Lancet. 1: Press M, Tamborlane WV, Sherwin RS Importance of raised growth hormone levels in mediating the metabolic derangements of diabetes. N Engl J Med. 310: Merimee TJ, Fitzgerald CR, Gold LA, McCourt JP Characteristics of growth hormone secretion in clinically stable diabetes. Diabetes. 28: Hayford JT, Danney MM, Hendrix JA, Thompson RG Integrated concentration of growth hormone in juvenile-onset diabetes. Diabetes. 29: Schaper NC, Verhoeff AJ, Sluiter WJ, Roelse H, Reitsma WD, Doorenbos H The growth hormone response to growth hormone-releasing hormone and its relationship to serum insulin-like growth factor I in type I diabetes mellitus. Acta Endocrinol (Copenh). 122: Kopelman PG, Mason AC, Noonan K, Monson JP Growth hormone response to growth hormone releasing factor in diabetic men. Clin Endocrinol (Oxf). 28: Cordido F, Peñalva A, Diéguez C, Casanueva FF Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6:evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab. 76: Popovic V, Damjanovic S, Micic D, Petakov M, Diéguez C, Casanueva FF Growth hormone (GH) secretion in active acromegaly after the combined administration of GH-releasing hormone and GH-releasing peptide. J Clin Endocrinol Metab. 79: Leal-Cerro A, Pumar A, García E, Diéguez C, Casanueva FF Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing s syndrome. Clin Endocrinol (Oxf). 41: Pombo M, Barreiro J, Peñalva A, Mallo F, Casanueva FF, Diéguez C Plasma growth hormone response to growth hormone releasing hexapeptide (GHRP-6) in children with short stature. Acta Paediatr. 84: Micic D, Kendereski A, Popovic V, et al Growth hormone response to GHRH, GHRP-6 and GHRH GHRP-6 in patients with polycystic ovary syndrome. Clin Endocrinol (Oxf). 45: Howard AD, Feighner SD, Cully DF et al A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 273: Popovic V, Damjanovic S, Micic D, Djurovic M, Diéguez C, Casanueva FF Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J Clin Endocrinol Metab. 80: Maccario M, Arvat E, Procopio M, et al Metabolic modulation of the growth hormone-releasing activity of hexarelin in man. Metabolism. 44:
BIOM2010 (till mid sem) Endocrinology. e.g. anterior pituitary gland, thyroid, adrenal. Pineal Heart GI Female
BIOM2010 (till mid sem) Endocrinology Endocrine system Endocrine gland : a that acts by directly into the which then to other parts of the body to act on (cells, tissues, organs) : found at e.g. anterior
More informationSermorelin as an Alternative to hgh for Treating GH Insufficiency of Aging
Sermorelin as an Alternative to hgh for Treating GH Insufficiency of Aging Richard F. Walker, Ph.D., R.Ph., Executive Director, Society for Applied Research in Aging (SARA) (www.agesociety.org) SOMATOPAUSE
More informationEuropean Journal of Endocrinology (2003) ISSN
European Journal of Endocrinology (2003) 149 117 122 ISSN 0804-4643 CLINICAL STUDY Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus
More informationThe role of endogenous GHRH in arginine-, insulin-, clonidineand
European Journal of Endocrinology (2002) 146 197 202 ISSN 0804-4643 CLINICAL STUDY The role of endogenous GHRH in arginine-, insulin-, clonidineand L-dopa-induced GH release in normal subjects Kunihiko
More informationX/00/$03.00/0 Vol. 85, No. 4 The Journal of Clinical Endocrinology & Metabolism Copyright 2000 by The Endocrine Society
0021-972X/00/$03.00/0 Vol. 85, No. 4 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2000 by The Endocrine Society Diagnosis of Growth Hormone (GH) Deficiency in Adults with
More informationGrowth Hormone, Somatostatin, and Prolactin 1 & 2 Mohammed Y. Kalimi, Ph.D.
Growth Hormone, Somatostatin, and Prolactin 1 & 2 Mohammed Y. Kalimi, Ph.D. I. Growth Hormone (somatotropin): Growth hormone (GH) is a 191 amino acid single chain polypeptide (MW 22,000 daltons). Growth
More informationGhrelin and the enteroinsular axis in healthy men
HORMONES 2007, 6(4):321-326 Research paper Ghrelin and the enteroinsular axis in healthy men Dragan Micic, 1 Leonidas Duntas, 2,3 Goran Cvijovic, 1 Aleksandra Kendereski, 1 Mirjana Sumarac-Dumanovic, 1
More informationMelatonin and Growth Hormone Deficiency: A Contribution to the Evaluation of Neuroendocrine Disorders
Melatonin and Growth Hormone Deficiency: A Contribution to the Evaluation of Neuroendocrine Disorders Fideleff G., Suárez M., Boquete HR, Azaretzky M., Sobrado P., Brunetto O*, Fideleff HL Endocrinology
More informationX/99/$03.00/0 Vol. 84, No. 1 Journal of Clinical Endocrinology and Metabolism Copyright 1999 by The Endocrine Society
0021-972X/99/$03.00/0 Vol. 84, No. 1 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1999 by The Endocrine Society Effects of Recombinant Human Insulin-Like Growth Factor I
More informationAetna Better Health of Virginia
Genotropin Nutropin Serostim Zomacton Humatrope Omnitrope Zorbtive somatropin Norditropin Saizen General Criteria for Approval: Omnitrope vial formulation is the preferred Growth Hormone product; consideration
More informationPhysiological processes controlled by hormones?
: the study of hormones, their receptors, the intracellular signaling pathways they invoke, and the diseases and conditions associated with them. What are hormones? Major endocrine glands? Fig 7-2 Physiological
More informationChange in Somatostatinergic Tone of Acromegalic Patients according to the Size of Growth Hormone-Producing Pituitary Tumors
ORIGINAL ARTICLE Endocrinology, Nutrition & Metabolism http://dx.doi.org/1.3346/jkms.213.28.12.1774 J Korean Med Sci 213; 28: 1774-178 Change in Somatostatinergic Tone of Acromegalic Patients according
More informationHigh and Low GH: an update of diagnosis and management of GH disorders
High and Low GH: an update of diagnosis and management of GH disorders Georgia Chapter-AACE 2017 Laurence Katznelson, MD Professor of Medicine and Neurosurgery Associate Dean of Graduate Medical Education
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: December 5, 2014 Growth Hormone Adult
More informationX/97/$03.00/0 Vol. 82, No. 10 Journal of Clinical Endocrinology and Metabolism Copyright 1997 by The Endocrine Society
0021-972X/97/$03.00/0 Vol. 82, No. 10 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1997 by The Endocrine Society Oral Administration of Growth Hormone (GH) Releasing Peptide-Mimetic
More informationGrowth Hormone (GH) Status and Body Composition in Normal Ageing and in Elderly Adults with GH Deficiency
Somatopause and Elderly GHD Similarities and Differences Horm Res 2003;60(suppl 1):105 111 DOI: 10.1159/000071234 Growth Hormone (GH) Status and Body Composition in Normal Ageing and in Elderly Adults
More informationGrowth IGF Analyte Information
Growth IGF-1 Analyte Information - 1 - IGF-1 Introduction Insulin-like growth factor 1 (IGF-1, IGF-I) is a single chain polypeptide containing 70 amino acids and three disulfide bridges. It is structurally
More informationEndocrine part one. Presented by Dr. Mohammad Saadeh The requirements for the Clinical Chemistry Philadelphia University Faculty of pharmacy
Endocrine part one Presented by Dr. Mohammad Saadeh The requirements for the Clinical Chemistry Philadelphia University Faculty of pharmacy HORMONES Hormones are chemicals released by a cell or a gland
More informationInteraction between glucagon and Hexarelin, a peptidyl GH secretagogue, on somatotroph and corticotroph secretion in humans
European Journal of Endocrinology (2000) 143 601±606 ISSN 0804-4643 CLINICAL STUDY Interaction between glucagon and Hexarelin, a peptidyl GH secretagogue, on somatotroph and corticotroph secretion in humans
More informationPROVOCATIVE TESTING OF HUMAN GROWTH HORMONE RELEASE IN SHORT STATURED CHILDREN
PROVOCATIVE TESTING OF HUMAN GROWTH HORMONE RELEASE IN SHORT STATURED CHILDREN Pages with reference to book, From 256 To 261 Qaisar Hussain Siraj, Asma Inam-ur-Rehman, Amin Waqar, Syed Azhar Ahmed ( Nuclear
More informationRequest for Prior Authorization Growth Hormone (Norditropin
Request for Prior Authorization Growth Hormone (Norditropin, Nutropin/AQ ) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Growth Hormone require a
More informationTwenty-four Hour Plasma GH, FSH and LH Profiles in Patients with Turner's Syndrome
Twenty-four Hour Plasma GH, FSH and LH Profiles in Patients with Turner's Syndrome MARIA CORAZON R. VILLADOLID, KAZUE TAKANO, NAOMI HIZUKA, KUMIKO ASAKAWA, IZUMI SUKEGAWA, REIKO HORIKAWA AND KAZUO SHIZUME
More informationThe Role of Oral Growth Hormone Secretagogues in Anti-Aging Therapy
References 1. American Journal of Clinical Nutrition 1995: 61(5): 1058-61. 2. Methods Find Exp Clin Pharmacol (Spain), May 1990, 12(4) p275-9. 3. Acta Paediatr Suppl (Sweden), Mar 1993, 388 p10-5. 4. Baum,
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents
Aetna Better Health 2000 Market Street, Suite 850 Philadelphia, PA 19103 AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents Revised April 2014 Growth
More informationCIGNA HealthCare Prior Authorization Form - Growth Hormone Medications -
Pharmacy Services Phone: (800)244-6224 Fax: (800)390-9745 CIGNA HealthCare Prior Authorization Form - Growth Hormone Medications - Notice: Failure to complete this form in its entirety may result in delayed
More information/02/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 87(5): Copyright 2002 by The Endocrine Society
0013-7227/02/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 87(5):2067 2079 Printed in U.S.A. Copyright 2002 by The Endocrine Society Sensitivity and Specificity of Six Tests for the Diagnosis
More informationTesamorelin Clinical Data Overview Jean-Claude Mamputu, PhD Senior Medical Advisor, Theratechnologies
Tesamorelin Clinical Data Overview Jean-Claude Mamputu, PhD Senior Medical Advisor, Theratechnologies Copyright 2016. All Rights Reserved. Property of Theratechnologies Inc. Mechanism of Action of Tesamorelin
More informationIncreasing Growth Hormone with and without using Growth Hormone
Increasing Growth Hormone with and without using Growth Hormone Edwin Lee, M.D., F.A.C.E. Institute for Hormonal Balance Orlando, FL Disclosure The following potential conflict of interest relationships
More informationHypothalamus & Pituitary Gland
Hypothalamus & Pituitary Gland Hypothalamus and Pituitary Gland The hypothalamus and pituitary gland form a unit that exerts control over the function of several endocrine glands (thyroid, adrenals, and
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Zomacton (aka. Tev-Tropin)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.12 Subject: Growth Hormone Pediatric Page: 1 of 6 Last Review Date: September 15, 2016 Growth Hormone
More information2 GHRP Historical Perspective
Chapter 2 / GHRP Historical Perspective 17 2 GHRP Historical Perspective Basic and Clinical C. Y. Bowers, MD CONTENTS INTRODUCTION HISTORICAL BACKGOUND REFERENCES INTRODUCTION The growth hormone releasing
More informationEndocrine part two. Presented by Dr. Mohammad Saadeh The requirements for the Clinical Chemistry Philadelphia University Faculty of pharmacy
Endocrine part two Presented by Dr. Mohammad Saadeh The requirements for the Clinical Chemistry Philadelphia University Faculty of pharmacy Cushing's disease: increased secretion of adrenocorticotropic
More informationGROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT
1. Medical Condition TUEC Guidelines GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT Growth Hormone Deficiency and other indications for growth hormone therapy
More informationNROSCI/BIOSC 1070 and MSNBIO 2070 September 11, 2017 Control Mechanisms 2: Endocrine Control
NROSCI/BIOSC 1070 and MSNBIO 2070 September 11, 2017 Control Mechanisms 2: Endocrine Control Hormones are chemical messengers that are secreted into the blood by endocrine cells or specialized neurons.
More informationATHLETES & PRESCRIBING PHYSICIANS PLEASE READ
ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ USADA can grant a Therapeutic Use Exemption (TUE) in compliance with the World Anti-Doping Agency International Standard for TUEs. The TUE application process
More informationHypothalamic & Pituitary Hormones
1 Hypothalamic & Pituitary Hormones Pharmacologic Applications: Drugs that mimic or block the effects of hypothalamic or pituitary hormones have the following applications: 1. Replacement therapy for hormone
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Growth Hormone (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More information28 Regulation of Fasting and Post-
28 Regulation of Fasting and Post- Prandial Glucose Metabolism Keywords: Type 2 Diabetes, endogenous glucose production, splanchnic glucose uptake, gluconeo-genesis, glycogenolysis, glucose effectiveness.
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: December 8, 2017 Growth Hormone Adult
More informationHormones. Introduction to Endocrine Disorders. Hormone actions. Modulation of hormone levels. Modulation of hormone levels
Introduction to Endocrine Disorders Hormones Self-regulating system (homeostasis) Affect: Growth Metabolism Reproduction Fluid and electrolyte balance Hormone actions Endocrine gland Hormone synthesis
More informationAlternative insulin delivery systems: how demanding should the patient be?
Diabetologia (1997) 4: S97 S11 Springer-Verlag 1997 Alternative insulin delivery systems: how demanding should the patient be? K.S. Polonsky, M. M. Byrne, J. Sturis Department of Medicine, The University
More informationChanges and clinical significance of serum vaspin levels in patients with type 2 diabetes
Changes and clinical significance of serum vaspin levels in patients with type 2 diabetes L. Yang*, S.J. Chen*, G.Y. Yuan, D. Wang and J.J. Chen Department of Endocrinology, Affiliated Hospital of Jiangsu
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: September 15, 2016 Growth Hormone
More information13 Common Endocrine INTRODUCTION CHANGES IN GH/IGF-1 AXIS
13 Common Endocrine Abnormalities in ICU Abstract: With sophisticated mechanical devices and monitoring systems, mortality and morbidity in the critically ill patients in the intensive care units (ICU)
More informationDiabetes: What is the scope of the problem?
Diabetes: What is the scope of the problem? Elizabeth R. Seaquist MD Division of Endocrinology and Diabetes Department of Medicine Director, General Clinical Research Center Pennock Family Chair in Diabetes
More informationHormonal Regulations Of Glucose Metabolism & DM
Hormonal Regulations Of Glucose Metabolism & DM What Hormones Regulate Metabolism? What Hormones Regulate Metabolism? Insulin Glucagon Thyroid hormones Cortisol Epinephrine Most regulation occurs in order
More informationGrowth Hormone Therapy
Growth Hormone Therapy Policy Number: Original Effective Date: MM.04.011 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/23/2014 Section: Prescription Drugs Place(s)
More informationHypothalamus & pituitary gland
Hypothalamus & pituitary gland Huiping Wang ( 王会平 ), PhD Department of Physiology Rm C541, Block C, Research Building, School of Medicine Tel: 88208292 Outline Hypothalamus Relationship between the hypothalamus
More informationGrowth Hormone-Releasing Peptide-2 (GHRP-2) Acts Synergistically with Growth Hormone-Releasing Hormone (GHRH) to Release Growth Hormone (GH) in Swine
Growth Hormone-Releasing Peptide-2 (GHRP-2) Acts Synergistically with Growth Hormone-Releasing Hormone (GHRH) to Release Growth Hormone (GH) in Swine Long Thang PHUNG1, Nobuyoshi MATSUNAGA, Satoshi HIDAKA,
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Zomacton
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: September 20, 2018 Growth Hormone
More informationOral arginine attenuates the growth hormone response to resistance exercise
J Appl Physiol 101: 848 852, 2006. First published June 1, 2006; doi:10.1152/japplphysiol.00285.2006. Oral arginine attenuates the growth hormone response to resistance exercise S. R. Collier, E. Collins,
More informationThe endocrine system is complex and sometimes poorly understood.
1 CE Credit Testing the Endocrine System for Adrenal Disorders and Diabetes Mellitus: It Is All About Signaling Hormones! David Liss, BA, RVT, VTS (ECC) Platt College Alhambra, California For more information,
More informationSomatotroph Pituitary Adenomas (Acromegaly) The Diagnostic Pathway (11-2K-234)
Somatotroph Pituitary Adenomas (Acromegaly) The Diagnostic Pathway (11-2K-234) Common presenting symptoms/clinical assessment: Pituitary adenomas are benign neoplasms of the pituitary gland. In patients
More informationCLINICAL UTILITY OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN PATIENTS WITH TYPE 1 DIABETES: A MACEDONIAN REPORT
University Department of Endocrinology, Diabetes and Metabolic Disorders, Medical Faculty, Sv. Kiril I Metodij University, Skopje, Macedonia Scientific Paper Received: February 19, 2007 Accepted: March
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Mecasermin Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5 References... 5 Effective Date... 5/15/2017 Next
More informationInsulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness
Insulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness Prepared for: Agency for Healthcare Research and Quality (AHRQ) www.ahrq.gov Outline of Material Introduction
More informationThe Growth Hormone/Insulin-Like Growth Factor-1 Axis in Health and Disease Prof. Derek LeRoith
The Growth Hormone/Insulin-Like Growth Factor-1 Axis in Health and Disease Derek LeRoith MD PhD Division of Endocrinology, Diabetes and Bone Diseases Mt Sinai School of Medicine, NY 1 GH/IGF-1 axis Agenda:
More informationEffects of Novel Growth Hormone Secretagogues on Growth Hormone Secretion in Farm Animals
Beef Research Report, 1996 Animal Science Research Reports 1997 Effects of Novel Growth Hormone Secretagogues on Growth Hormone Secretion in Farm Animals Lloyd L. Anderson Iowa State University Follow
More informationType 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM
Type 2 DM in Adolescents: Use of GLP-1 RA Objectives Identify patients in the pediatric population with T2DM that would potentially benefit from the use of GLP-1 RA Discuss changes in glycemic outcomes
More informationEndocrine Pharmacology
Endocrine Pharmacology 17-2-2013 DRUGS AFFECTING THE ENDOCRINE SYSTEM The endocrine system is the system of glands, each of which secretes a type of hormone directly into the bloodstream to regulate the
More informationWeek 3, Lecture 5a. Pathophysiology of Diabetes. Simin Liu, MD, ScD
Week 3, Lecture 5a Pathophysiology of Diabetes Simin Liu, MD, ScD General Model of Peptide Hormone Action Hormone Plasma Membrane Activated Nucleus Cellular Trafficking Enzymes Inhibited Receptor Effector
More informationHormonal regulation of. Physiology Department Medical School, University of Sumatera Utara
Hormonal regulation of nutrient metabolism Physiology Department Medical School, University of Sumatera Utara Homeostasis & Controls Successful compensation Homeostasis reestablished Failure to compensate
More informationGH Replacement Therapy in Growth Hormone Deficient Adults
GH Replacement Therapy in Growth Hormone Deficient Adults Sequence of hormone loss in hypopituitarism depending on location of a benign tumor Besser GM, Cudworth AG, eds. Clinical endocrinology: an illustrated
More informationNormalization of Growth Hormone
Downloaded from http://www.jci.org on November 24, 217. https://doi.org/1.1172/jci16671 Normalization of Growth Hormone Hyperresponse to Exercise in Juvenile Diabetics after "Normalization" of Blood Sugar
More informationR ecombinant growth hormone (GH) treatment is recommended
126 ORIGINAL ARTICLE The investigation of short stature: a survey of practice in Wales and suggested practical guidelines C Evans, J W Gregory, on behalf of the All Wales Clinical Biochemistry Audit Group...
More informationThe diagnosis of GH deficiency in obese patients: a reappraisal with GHRH plus arginine testing after pharmacological blockade of lipolysis
European Journal of Endocrinology (0) 13 01 0 ISSN 00-3 CLINICAL STUDY The diagnosis of GH deficiency in obese patients: a reappraisal with GHRH plus arginine testing after pharmacological blockade of
More informationMonday, 7 th of July 2008 ( ) University of Buea MED30. (GENERAL ENDOCRINOLOGY) Exam ( )
.. Monday, 7 th of July 2008 (8 30-11. 30 ) Faculty of Health Sciences University of Buea MED30 304 Programme in Medicine (GENERAL ENDOCRINOLOGY) Exam (2007-2008).. Multiple Choice Identify the letter
More informationGROWTH HORMONE AND AMINO ACIDS
GROWTH HORMONE AND AMINO ACIDS Certain amino acids when combined with one another and ingested will cause an increase in growth hormone levels in humans. The increase in the body's production of growth
More informationDiagnosing Growth Disorders. PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health
Diagnosing Growth Disorders PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health Content Normal pattern of growth and its variation Using growth charts Interpreting auxological
More informationGrowth Hormone!gents. WA.PHAR.50 Growth Hormone Agents
Growth Hormone!gents WA.PHAR.50 Growth Hormone Agents Background: Human growth hormone, also known as somatotropin, is produced in the anterior lobe of the pituitary gland. This hormone plays an important
More informationCHAPTER 50 Endocrine Systems. Copyright The McGraw-Hill Companies, Inc. Permission required for reproduction or display.
CHAPTER 50 Endocrine Systems Copyright The McGraw-Hill Companies, Inc. Permission required for reproduction or display. Endocrine system All the endocrine glands and other organs with hormonesecreting
More informationGrowth Hormone & IGF Research
Growth Hormone & IGF Research xxx (29) xxx xxx Contents lists available at ScienceDirect Growth Hormone & IGF Research journal homepage: www.elsevier.com/locate/ghir Pharmacodynamic hormonal effects of
More informationLiving Control Mechanisms
Living Control Mechanisms Dr Kate Earp MBChB MRCP Specialty Registrar Chemical Pathology & Metabolic Medicine kate.earp@sth.nhs.uk 15/10/2015 Contents Aims & objectives Homeostasis Cell communication Introduction
More informationSomatostatin is an endogenous peptide and neurotransmitter
Rapid Publication Somatostatin Impairs Clearance of Exogenous Insulin in Humans ELI IPP, YSEF SINAI, BENJAMIN BAR-Z, RAFAEL NESHER, AND ERL CERASI SUMMARY Somatostatin has been widely used to suppress
More informationDiabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE
Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized
More informationThe enteroinsular axis in the pathogenesis of prediabetes and diabetes in humans
The enteroinsular axis in the pathogenesis of prediabetes and diabetes in humans Young Min Cho, MD, PhD Division of Endocrinology and Metabolism Seoul National University College of Medicine Plasma glucose
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationReview Article Glucagon Stimulation Testing in Assessing for Adult Growth Hormone Deficiency: Current Status and Future Perspectives
International Scholarly Research Network ISRN Endocrinology Volume 2011, Article ID 608056, 6 pages doi:10.5402/2011/608056 Review Article Glucagon Stimulation Testing in Assessing for Adult Growth Hormone
More informationTherapeutic strategy to reduce Glucagon secretion
Clinical focus on glucagon: α-cell as a companion of β-cell Therapeutic strategy to reduce Glucagon secretion Sunghwan Suh Dong-A University Conflict of interest disclosure None Committee of Scientific
More informationEffects of growth hormone secretagogue receptor agonist and antagonist in nonobese type 2 diabetic MKR mice
Effects of growth hormone secretagogue receptor agonist and antagonist in nonobese type 2 diabetic MKR mice Rasha Mosa (MBCHC, M.D, PhD candidate) School of Biomedical Sciences University of Queensland
More informationOkay to start off today, these are the fundamentals that we are going to use for the whole system.
Good morning, Today we are going to start our lecture about the endocrine pharmacology. we will be having 7 lectures covering most of the topics. As you have got accustomed to my style, I am not going
More informationEffect of L-5-HTP on the Release of Growth Hormone, TSH and Insulin
Endocrinol. Japon. 1973, 20 (2), 135,-441 Effect of L-5-HTP on the Release of Growth Hormone, TSH and Insulin MANABU YOSHIMURA, YUKIO OCHI, TADAYOSHI MIYAZAKI, KATSUHIKO SHIOMI AND TAKASHI HACHIYA 2nd
More informationGeneral Approval Criteria for ALL Growth Hormone agents: (ALL criteria must be met)
Growth Hormone Agents Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Page 1 of 7 Preferred Agents Somatropin Pen (Norditropin ) Somatropin Pen (Nutropin AQ ) Non-Preferred
More informationInsulin Secretion in Diabetes Mellitus
A Role for AlphaAdrenergic Receptors in Abnormal nsulin Secretion in Diabetes Mellitus R. PAUL ROBERTSON, JEFFREY B. HALTER, and DANiEL PORTE, JR. From the University of Washington School of Medicine and
More informationHomeostasis Through Chemistry. The Endocrine System Topic 6.6
Homeostasis Through Chemistry The Endocrine System Topic 6.6 Comparing NS & ES Animals have two systems of internal communication and regulation The nervous system Response time: Fast, quick Signals: electrical
More informationRelationship between Plasma (IGF-l) Levels and Body Mass. Insulin-like Growth Factor Index (BMI) in Adults
Endocrine Journal 1993, 40 (1), 41-45 Relationship between Plasma (IGF-l) Levels and Body Mass Insulin-like Growth Factor Index (BMI) in Adults HIROYuKI YAMAMOTO AND YUZURU KATO First Division, Department
More informationAN AGE-related decrease in GH secretion has been
0021-972X/90/7106-1481$02.00/0 Journal of Clinical Endocrinology and Metabolism Copyright 1990 by The Endocrine Society Vol. 71, No. 6 Printed in U.S.A. Growth Hormone (GH) Responsiveness to Combined Administration
More informationMy Journey in Endocrinology. Samuel Cataland M.D
My Journey in Endocrinology Samuel Cataland M.D. 1968-2015 Drs Berson M.D. Yalow phd Insulin Radioimmunoassay Nobel Prize Physiology or Medicine 1977 Rosalyn Yalow: Radioimmunoassay Technology Andrew Schally
More informationGrowth Hormones DRUG.00009
Market DC Growth Hormones DRUG.00009 Override(s) Prior Authorization Quantity Limit Approval Duration WPM PAB Center: Thirty (30) day exception for recently expired (within the past 45 days) growth hormone
More informationPituitary Tumors and Incidentalomas. Bijan Ahrari, MD, FACE, ECNU Palm Medical Group
Pituitary Tumors and Incidentalomas Bijan Ahrari, MD, FACE, ECNU Palm Medical Group Background Pituitary incidentaloma: a previously unsuspected pituitary lesion that is discovered on an imaging study
More informationDM and Osteoporosis. Why is it important?
DM and Osteoporosis Why is it important? Diabetes Osteoporosis Fractures Dr Pedro Conthe HGUGM Madrid Spain Agenda: DM and Osteoporosis Observational studies Physiopathology of bone Type I and Type 2 DM
More informationManaging Acromegaly: Biochemical Control with SIGNIFOR LAR (pasireotide)
Managing Acromegaly: Biochemical Control with SIGNIFOR LAR (pasireotide) INDICATION AND USAGE SIGNIFOR LAR (pasireotide) for injectable suspension is a somatostatin analog indicated for the treatment of
More informationPasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line
Pasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line December 2010 This technology summary is based on information available at the time of research and a limited literature
More informationCortistatin-17 and -14 exert the same endocrine activities as somatostatin in humans
Growth Hormone & IGF Research 14 (24) 382 387 www.elsevier.com/locate/ghir Cortistatin-17 and -14 exert the same endocrine activities as somatostatin in humans C. Gottero a, F. Prodam a, S. Destefanis
More informationChapter 12 Endocrine System (export).notebook. February 27, Mar 17 2:59 PM. Mar 17 3:09 PM. Mar 17 3:05 PM. Mar 17 3:03 PM.
Endocrine System Hormones Chemical messengers released directly into the bloodstream Regulate: *May have wide spread effect or only affect certain tissues ** : cells with receptors that respond to specific
More informationIncrease Growth Hormone by 701% after only 90 minutes...naturally
BREAKTHROUGH UNIVERSITY STUDY REVEALS Increase Growth Hormone by 701% after only 90 minutes...naturally Summary key points 275% increase in insulin 701% increase in growth hormone 300% increase in IGF1
More information